Pregnancy following ovarian induction in a patient with premature ovarian failure and undetectable serum anti-Müllerian hormone

J Obstet Gynaecol Res. 2013 May;39(5):1070-2. doi: 10.1111/j.1447-0756.2012.02068.x. Epub 2013 Feb 4.

Abstract

We report the first case, to the best of our knowledge, of successful conception following ovarian induction in a patient with premature ovarian failure and undetectable serum anti-Müllerian hormone. A 34-year-old woman was referred because of ovarian amenorrhea. After endogenous gonadotrophins were normalized by hormone-replacement therapy and gonadotrophin-releasing hormone agonist, ovarian induction was performed using exogenous gonadotrophins. On ovarian induction day 8, one follicle had reached a mean diameter of 19.6 mm, the serum estradiol level had increased to 516 pg/mL, and human chorionic gonadotrophin (HCG) was injected. On HCG injection day 7, ultrasonography was unable to detect the follicle, and serum progesterone levels had increased to 6.1 ng/mL. One month after HCG injection, ultrasonography detected an intrauterine fetus with beating heart. Even with serum anti-Müllerian hormone levels below the threshold of detection, there is a chance for patients with premature ovarian failure.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Anti-Mullerian Hormone / blood
  • Embryo Implantation
  • Estrogen Replacement Therapy
  • Female
  • Fertility Agents, Female / therapeutic use
  • Gonadotropin-Releasing Hormone / antagonists & inhibitors
  • Humans
  • Infertility, Female / etiology
  • Infertility, Female / therapy*
  • Leuprolide / therapeutic use
  • Menotropins / therapeutic use
  • Ovulation Induction*
  • Pregnancy
  • Primary Ovarian Insufficiency / blood
  • Primary Ovarian Insufficiency / drug therapy
  • Primary Ovarian Insufficiency / physiopathology*
  • Severity of Illness Index

Substances

  • Fertility Agents, Female
  • Gonadotropin-Releasing Hormone
  • Menotropins
  • Anti-Mullerian Hormone
  • Leuprolide